| Literature DB >> 33483373 |
Tracy J Berg1, Carolina Marques2, Vasiliki Pantazopoulou1, Elinn Johansson1, Kristoffer von Stedingk3,4, David Lindgren1, Pauline Jeannot1, Elin J Pietras5, Tobias Bergström6, Fredrik J Swartling6, Valeria Governa7, Johan Bengzon8, Mattias Belting6,7, Håkan Axelson1, Massimo Squatrito2, Alexander Pietras9.
Abstract
The tumor microenvironment plays an essential role in supporting glioma stemness and radioresistance. Following radiotherapy, recurrent gliomas form in an irradiated microenvironment. Here we report that astrocytes, when pre-irradiated, increase stemness and survival of cocultured glioma cells. Tumor-naïve brains increased reactive astrocytes in response to radiation, and mice subjected to radiation prior to implantation of glioma cells developed more aggressive tumors. Extracellular matrix derived from irradiated astrocytes were found to be a major driver of this phenotype and astrocyte-derived transglutaminase 2 (TGM2) was identified as a promoter of glioma stemness and radioresistance. TGM2 levels increased after radiation in vivo and in recurrent human glioma, and TGM2 inhibitors abrogated glioma stemness and survival. These data suggest that irradiation of the brain results in the formation of a tumor-supportive microenvironment. Therapeutic targeting of radiation-induced, astrocyte-derived extracellular matrix proteins may enhance the efficacy of standard-of-care radiotherapy by reducing stemness in glioma. SIGNIFICANCE: These findings presented here indicate that radiotherapy can result in a tumor-supportive microenvironment, the targeting of which may be necessary to overcome tumor cell therapeutic resistance and recurrence. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/81/8/2101/F1.large.jpg. ©2021 American Association for Cancer Research.Entities:
Year: 2021 PMID: 33483373 DOI: 10.1158/0008-5472.CAN-20-1785
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701